ECM
RETA

Endurant Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Endurant Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,352
Closed -$612K – 78
2022
Q3 		$612K Buy
+24,352
New +$675K 0.2% 41
2018
Q2 		– Sell
-25,000
Closed -$513K – 82
2018
Q1 		$513K Buy
+25,000
New +$643K 0.19% 66

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Endurant Capital Management's RETA Position: Q4 2022 in Review

Endurant Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 24,352 shares — an estimated $612K sold.

Endurant Capital Management first reported a position in RETA in Q1 2018 and held it in 2 quarters. The position peaked at $612K in Q3 2022. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

  • Endurant Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • Endurant Capital Management sold 24,352 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $612K.
  • Endurant Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 2 quarters.
  • Endurant Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $612K in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Endurant Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.